Method for preparing brivaracetam and intermediate thereof

Patent metadata

Field	Value
Publication number	US-12116342-B2
Application number	US-201917312195-A
Country	US
Kind code	B2
Filing date	Dec 12, 2019
Priority date	Dec 19, 2018
Publication date	Oct 15, 2024
Grant date	Oct 15, 2024

Abstract

The present application relates to a method (I) for preparing a brivaracetam intermediate, comprising the steps of dissolving the compound represented by B-P and 1S,2S-diphenylethylenediamine in a solvent for resolution, crystallizing, filtering, and recrystallizing to obtain the compound represented by B-Q, which is then converted to the brivaracetam intermediate represented by B-R. This method can effectively resolve the compound represented by B-P. The present application also provides a method for preparing brivaracetam using the compound represented by B-R. The method can separate the effective components only through simple steps such as extraction, washing, drying, and concentration without requiring use of chiral chromatography column to separate isomers in the preparation process, and thus the separation process is simple, greatly reducing the production cost of brivaracetam.

First claim

The invention claimed is:

1. A method for preparing a brivaracetam intermediate represented by B-R, comprising the following steps:
(1) reacting a compound represented by B-P with 1S,2S-diphenylethylenediamine to obtain a compound represented by B-Q; and
(2) converting the compound represented by B-Q to the brivaracetam intermediate represented by B-R;

wherein step (1) comprising
a. adding the compound represented by B-P and 1S,2S-diphenylethylenediamine to a resolution solvent, heating until it is dissolved and clarified, then cooling to crystallize, and separating to obtain a crude solid product of the compound represented by B-Q;
b. recrystallizing the crude solid product in a recrystallization solvent to obtain a refined product of the compound represented by B-Q, and
wherein the resolution solvent in step a is at least one selected from the group consisting of methyl tertiary butyl ether, isopropyl ether, tetrahydrofuran, acetonitrile, ethyl acetate, isopropyl acetate, and ethylene glycol dimethyl ether.

2. The method according to claim 1 , wherein the molar ratio of the compound represented by B-P to 1S,2S-diphenylethylenediamine is 1:0.5-1.5.

3. The method according to claim 1 , wherein the volume to mass ratio of the resolution solvent to the compound represented by B-P is 1-30 mL: 1 g.

4. The method according to claim 1 , wherein in step a, heating is performed to a temperature of 25° C.-100° C.

5. The method according to claim 1 , wherein in step b, the recrystallization solvent is at least one selected from the group consisting of methyl tertiary butyl ether, acetonitrile, ethyl acetate, isopropyl acetate, and ethylene glycol dimethyl ether.

6. The method according to claim 1 , wherein the volume to mass ratio of the recrystallization solvent to the crude solid product of the compound represented by B-Q is 1-30 mL: 1 g.

7. The method according to claim 1 , wherein step (2) comprises:
c. converting the compound represented by B-Q to the brivaracetam intermediate represented by B-R in a reaction solvent comprising water in the presence of an acid.

8. The method according to claim 7 , wherein the acid in step c is at least one of hydrochloric acid and trifluoroacetic acid.

9. The method according to claim 7 , wherein the pH value of the reaction in step c is 1-2.

10. The method according to claim 7 , wherein in step c, the reaction solvent further comprises at least one of ethyl acetate and isopropyl acetate.

11. A method for preparing brivaracetam, comprising the following steps:
preparing the brivaracetam intermediate represented by B-R by using the method according to claim 1 ; and
ammoniating the brivaracetam intermediate represented by B-R to obtain brivaracetam.

12. The method according to claim 2 , wherein the molar ratio of the compound represented by B-P to 1S,2S-diphenylethylenediamine is 1:1.

13. The method according to claim 1 , wherein the resolution solvent in step a is at least one selected from the group consisting of isopropyl acetate, ethyl acetate, acetonitrile, and ethylene glycol dimethyl ether.

14. The method according to claim 3 , wherein the volume to mass ratio of the resolution solvent to the compound represented by B-P is 1-10 mL: 1 g.

15. The method according to claim 3 , wherein the volume to mass ratio of the resolution solvent to the compound represented by B-P is 3-6 mL: 1 g.

16. The method according to claim 4 , wherein in step a, heating is performed to a temperature of 50° C.-75° C.

17. The method according to claim 5 , wherein in step b, the recrystallization solvent is at least one selected from the group consisting of isopropyl acetate, acetonitrile, ethyl acetate and ethylene glycol dimethyl ether.

18. The method according to claim 6 , wherein the volume to mass ratio of the recrystallization solvent to the crude solid product of the compound represented by B-Q is 1-10 mL: 1 g.

Assignees

• Zhejiang Huahai Pharm Co Ltd
• Shanghai Syncores Tech Inc Ltd

Inventors

• Fan Haisheng
• Zhan Yipeng
• Yin Kai
• Ji Xiang
• Liu Fenghao
• Shi Kaiqiang
• Guo Xiaowen
• Huang Luning
• Tao Anping
• An Jianguo
• Gu Hong

Classifications

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07B2200/07

  Optical isomers · CPC title

• C07D207/27 Primary

  with substituted hydrocarbon radicals directly attached to the ring nitrogen atom · CPC title